TY - JOUR
T1 - Perspectives in immunotherapy
T2 - Meeting report from the "immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)
AU - Ascierto, Paolo A.
AU - Bifulco, Carlo
AU - Buonaguro, Luigi
AU - Emens, Leisha A.
AU - Ferris, Robert L.
AU - Fox, Bernard A.
AU - Delgoffe, Greg M.
AU - Galon, Jérôme
AU - Gridelli, Cesare
AU - Merlano, Marco
AU - Nathan, Paul
AU - Odunsi, Kunle
AU - Okada, Hideho
AU - Paulos, Chrystal M.
AU - Pignata, Sandro
AU - Schalper, Kurt A.
AU - Spranger, Stefani
AU - Tortora, Giampaolo
AU - Zarour, Hassane
AU - Butterfield, Lisa H.
AU - Puzanov, Igor
N1 - Publisher Copyright:
© 2019 The Author(s).
PY - 2019/11/29
Y1 - 2019/11/29
N2 - Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention on the immune contexture of the tumor microenvironment (TME), drivers of the immune response and mechanisms of tumor resistance to immunity. The development of novel immunotherapeutics and their use in combination with checkpoint inhibitors and other standard of care and novel treatment modalities is an area of particular attention across several tumor types, including melanoma, lung, ovarian, breast, pancreatic, renal, head and neck, brain and non-melanoma skin cancers. The 4th Immunotherapy Bridge meeting (28-29 November, 2018, Naples, Italy) focused on a wide range of evolving topics and trends in the field of cancer immunotherapy and key presentations from this meeting are summarised in this report.
AB - Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention on the immune contexture of the tumor microenvironment (TME), drivers of the immune response and mechanisms of tumor resistance to immunity. The development of novel immunotherapeutics and their use in combination with checkpoint inhibitors and other standard of care and novel treatment modalities is an area of particular attention across several tumor types, including melanoma, lung, ovarian, breast, pancreatic, renal, head and neck, brain and non-melanoma skin cancers. The 4th Immunotherapy Bridge meeting (28-29 November, 2018, Naples, Italy) focused on a wide range of evolving topics and trends in the field of cancer immunotherapy and key presentations from this meeting are summarised in this report.
KW - Biomarkers
KW - Checkpoint inhibitors
KW - Combination therapy
KW - Immunotherapy
KW - Tumor microenvironment
UR - https://www.scopus.com/pages/publications/85075782019
U2 - 10.1186/s40425-019-0798-3
DO - 10.1186/s40425-019-0798-3
M3 - Review article
C2 - 31783779
AN - SCOPUS:85075782019
SN - 2051-1426
VL - 7
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 1
M1 - 332
ER -